Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix hexa + Menitorix
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to the co-administration or comparative study of two GlaxoSmithKline vaccines: **Infanrix hexa** and **Menitorix**. Infanrix hexa is a hexavalent vaccine (DTPa-HBV-IPV/Hib) that provides active immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib). Menitorix is a combined conjugate vaccine providing protection against Haemophilus influenzae type b and Neisseria meningitidis serogroup C (MenC). The clinical context for this combination typically involves Phase III extension studies evaluating the long-term persistence of antibodies and the safety of booster doses in children who were previously primed with various DTPa-based combinations. Both vaccines utilize tetanus toxoid as a carrier protein for their polysaccharide components and are formulated with aluminum-based adjuvants to enhance the immune response.
- Brand names
- Infanrix hexaMenitorix
- Other names
- Infanrix hexa + MenitorixDTPa-HBV-IPV/Hib + Hib-MenC
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)HBsAg (Hepatitis B surface antigen)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)Neisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)
Beyond the preview
Go deeper on Infanrix hexa + Menitorix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix hexa + Menitorix.